ArticleNutrition research and practice2026
Protective effects of
Article in Nutrition research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesThis study examined the neuroprotective effects of MATERIALS/
methodsLM1060 (1 × 10
resultsLM1060 showed a protective effect against scopolamine-induced cognitive dysfunction, as confirmed by behavioral tests including the Y-maze and novel object recognition tests. Oral administration of LM1060 restored the ACh and ChAT activity reduced by scopolamine. The β-secretase activity and β-amyloid levels decreased after the LM1060 and DO treatment. The LM1060 administration group exhibited a higher protective effect against scopolamine-induced DNA damage in brain tissue than the scopolamine-treated group. In vitro studies showed that LM1060 significantly enhanced the cell viability and antioxidant capacity, reduced LDH release and AChE activity, and modulated inflammatory cytokine gene expression by downregulating interleukin (IL)-1β and IL-6 and upregulating IL-10.
conclusion
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.